370 related articles for article (PubMed ID: 7817873)
1. Rotaviruses: immunological determinants of protection against infection and disease.
Offit PA
Adv Virus Res; 1994; 44():161-202. PubMed ID: 7817873
[TBL] [Abstract][Full Text] [Related]
2. Reassortant rotaviruses containing structural proteins vp3 and vp7 from different parents induce antibodies protective against each parental serotype.
Offit PA; Clark HF; Blavat G; Greenberg HB
J Virol; 1986 Nov; 60(2):491-6. PubMed ID: 3021983
[TBL] [Abstract][Full Text] [Related]
3. Heterotypic protection and induction of a broad heterotypic neutralization response by rotavirus-like particles.
Crawford SE; Estes MK; Ciarlet M; Barone C; O'Neal CM; Cohen J; Conner ME
J Virol; 1999 Jun; 73(6):4813-22. PubMed ID: 10233942
[TBL] [Abstract][Full Text] [Related]
4. Infant immune response to human rotavirus serotype G1 vaccine candidate reassortant WI79-9: different dose response patterns to virus surface proteins VP7 and VP4.
Clark HF; Lawley D; Shrager D; Jean-Guillaume D; Offit PA; Whang SY; Eiden JJ; Bennett PS; Kaplan KM; Shaw AR
Pediatr Infect Dis J; 2004 Mar; 23(3):206-11. PubMed ID: 15014293
[TBL] [Abstract][Full Text] [Related]
5. Serum-neutralizing antibody to VP4 and VP7 proteins in infants following vaccination with WC3 bovine rotavirus.
Ward RL; Knowlton DR; Greenberg HB; Schiff GM; Bernstein DI
J Virol; 1990 Jun; 64(6):2687-91. PubMed ID: 2159538
[TBL] [Abstract][Full Text] [Related]
6. Divergence of VP7 genes of G1 rotaviruses isolated from infants vaccinated with reassortant rhesus rotaviruses.
Jin Q; Ward RL; Knowlton DR; Gabbay YB; Linhares AC; Rappaport R; Woods PA; Glass RI; Gentsch JR
Arch Virol; 1996; 141(11):2057-76. PubMed ID: 8973523
[TBL] [Abstract][Full Text] [Related]
7. WC3 reassortant vaccines in children.
Clark HF; Offit PA; Ellis RW; Krah D; Shaw AR; Eiden JJ; Pichichero M; Treanor JJ
Arch Virol Suppl; 1996; 12():187-98. PubMed ID: 9015115
[TBL] [Abstract][Full Text] [Related]
8. Relative importance of rotavirus-specific effector and memory B cells in protection against challenge.
Moser CA; Cookinham S; Coffin SE; Clark HF; Offit PA
J Virol; 1998 Feb; 72(2):1108-14. PubMed ID: 9445006
[TBL] [Abstract][Full Text] [Related]
9. Identification of VP7 epitopes associated with protection against human rotavirus illness or shedding in volunteers.
Green KY; Kapikian AZ
J Virol; 1992 Jan; 66(1):548-53. PubMed ID: 1370092
[TBL] [Abstract][Full Text] [Related]
10. Comparison of mucosal and systemic humoral immune responses and subsequent protection in mice orally inoculated with a homologous or a heterologous rotavirus.
Feng N; Burns JW; Bracy L; Greenberg HB
J Virol; 1994 Dec; 68(12):7766-73. PubMed ID: 7966566
[TBL] [Abstract][Full Text] [Related]
11. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants.
Clark HF; Offit PA; Ellis RW; Eiden JJ; Krah D; Shaw AR; Pichichero M; Treanor JJ; Borian FE; Bell LM; Plotkin SA
J Infect Dis; 1996 Sep; 174 Suppl 1():S73-80. PubMed ID: 8752294
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of protection against rotavirus infection and disease.
Ward R
Pediatr Infect Dis J; 2009 Mar; 28(3 Suppl):S57-9. PubMed ID: 19252425
[TBL] [Abstract][Full Text] [Related]
13. Induction of mucosal immune responses and protection against enteric viruses: rotavirus infection of gnotobiotic pigs as a model.
Yuan L; Saif LJ
Vet Immunol Immunopathol; 2002 Sep; 87(3-4):147-60. PubMed ID: 12072229
[TBL] [Abstract][Full Text] [Related]
14. Homotypic and heterotypic serum neutralizing antibody response to rotavirus proteins following natural primary infection and reinfection in children.
Gorrell RJ; Bishop RF
J Med Virol; 1999 Feb; 57(2):204-11. PubMed ID: 9892409
[TBL] [Abstract][Full Text] [Related]
15. Possible mechanisms of protection elicited by candidate rotavirus vaccines as determined with the adult mouse model.
Ward RL
Viral Immunol; 2003; 16(1):17-24. PubMed ID: 12725685
[TBL] [Abstract][Full Text] [Related]
16. Heterotypic protection following oral immunization with live heterologous rotaviruses in a mouse model.
Feng N; Vo PT; Chung D; Vo TV; Hoshino Y; Greenberg HB
J Infect Dis; 1997 Feb; 175(2):330-41. PubMed ID: 9203654
[TBL] [Abstract][Full Text] [Related]
17. Dual Recognition of Sialic Acid and αGal Epitopes by the VP8* Domains of the Bovine Rotavirus G6P[5] WC3 and of Its Mono-reassortant G4P[5] RotaTeq Vaccine Strains.
Alfajaro MM; Kim JY; Barbé L; Cho EH; Park JG; Soliman M; Baek YB; Kang MI; Kim SH; Kim GJ; Park SI; Pendu JL; Cho KO
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243129
[TBL] [Abstract][Full Text] [Related]
18. Rotavirus vaccine administered parenterally induces protective immunity.
Conner ME; Crawford SE; Barone C; Estes MK
J Virol; 1993 Nov; 67(11):6633-41. PubMed ID: 8411366
[TBL] [Abstract][Full Text] [Related]
19. Serologic and mucosal immune response to rotavirus infection in the rabbit model.
Conner ME; Gilger MA; Estes MK; Graham DY
J Virol; 1991 May; 65(5):2562-71. PubMed ID: 1850029
[TBL] [Abstract][Full Text] [Related]
20. Rotavirus-specific cytotoxic T lymphocyte response of mice after oral inoculation with candidate rotavirus vaccine strains RRV or WC3.
Offit PA; Svoboda YM
J Infect Dis; 1989 Nov; 160(5):783-8. PubMed ID: 2553826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
